AMERICA CLINICAL TRIALS
America Clinical Trials, originally founded in 2002 as a department of the Metabolic Institute of America, has developed into a major research institute bearing its name in 2012. ACT is led by a nationally-recognized medical metabolic leader, Yehuda Handelsman, MD as principal investigator and in coordination with other physician leaders serving as investigators for various studies.
To benefit the medical scientific community and
improve healthcare through advancement of clinical research.
1. To constantly improve our knowledge and innovation in research
for the benefit of public health and supporters.
2. To partner with the most advanced medical development companies
to bring new management modalities to healthcare.
3. To provide a state-of-the-art facility for our clinical research
for the betterment of our patients and sponsors.
4. To help develop the best and safest therapies for the future.
N.C.M.A., N.C.P.T., EMT-B,
Senior Clinical Trials Coordinator
Mike has been a research study coordinator and lab technician for over 21 years. He has been leading studies in metabolic diseases and endocrinology, which include research in diabetes, lipid disorders, and high blood pressure. He acquired skills and was involved in research in immunology, infectious diseases, and HIV, as well as various hormonal conditions including vitamin D and parathyroid hormone disorder. Mike is experienced and proficient in conducting studies from Phase II through phase IV. Mike’s other skills include BLS Instructor, EMT, I.A.T.A. Certified, Medic with Ventura County Medical Reserve Corp., and Remote CRA for Clinical Cancer Trials. The following is a list of several recent studies:
Improving lipid profile in patients with dyslipidemia (2002)
Point-of-care vs. laboratory testing – Study for adherence on glycemia (2002)
Observational study on the effect of active vitamin D in the treatment of hyperparathyroidism (2003)
A potential new diabetes compound in Metformin-treated Subjects with T2DM (2006)
Comparison of long-acting insulin vs. oral in triple-agent therapy (2007)
A study of a potential new diabetes compound for the treatment of T2DM in treatment-naïve subjects (2007)
Treatment or prevention of diabetes with a cholesterol-lowering, non-absorbable drug which is also indicated for diabetes (2008)
Treatment of diabetes with a potentially new weight loss compound (2008)
Contact Mike at email@example.com